What we're reading, June 28, 2016: Illinois approves Aetna-Humana merger; Harvard Pilgrim Health Care reaches value-based payment agreements with Novartis and Eli Lilly; and the Supreme Court struck down key aspects of the Texas abortion law.
The insurance mega-mergers are facing increasing opposition, but not in Illinois. The Illinois Department of Insurance has approved Aetna’s purchase of Humana, conditional on the Department of Justice (DOJ)’s approval, reported The New York Times. The deal is still under review by the DOJ, which is reviewing competition concerns regarding Medicare Advantage. In Illinois, Medicare Advantage plans have enough competition.
Harvard Pilgrim Health Care has reached value-based payment agreements with Novartis and Eli Lilly. According to STAT, the insurer—the second largest in New England—will receive a discount from Novartis if Entresto does not yield a specified drop in hospitalizations and will accept a lower rebate from Eli Lilly if Trulicity outperforms rival medicines in lowering hemoglobin levels. Harvard Pilgrim already has a value-based deal with Amgen for Repatha, the PCSK9 inhibitor for lowering cholesterol.
The Supreme Court has ruled that a Texas abortion law placed an undue burden on women. The Court struck down key aspects of the abortion law, which has cast doubt on similar laws in nearly 2 dozen states, according to Kaiser Health News. The Texas law, if enforced, would mean only 10 clinics would be able to perform abortions, compared with more than 40 prior to the law. The Court ruled 5-3 that the law’s requirements “place a substantial obstacle in the path of women seeking a peviability abortion.” Such an undue burden violates the Constitution.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More